Mainz Biomed B.V. (MYNZ)
5.90
0.61 (11.53%)
At close: Jan 15, 2025, 10:30 AM
Company Description
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics.
It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests.
The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed B.V.
| Country | DE |
| IPO Date | Nov 5, 2021 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Guido Baechler |
Contact Details
Address: Robert Koch Strasse 50 Mainz, DE | |
| Website | https://mainzbiomed.com |
Stock Details
| Ticker Symbol | MYNZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001874252 |
| CUSIP Number | N5436L101 |
| ISIN Number | NL0015000LC2 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Guido Baechler | Chief Executive Officer & Executive Director |
| Dr. Christopher Von Torne P.M.P., Ph.D. | Chief Operating Officer |
| Dr. Frank Krieg-Schneider | Chief Technology Officer |
| William J. Caragol CPA | Chief Financial Officer |
| Dr. Moritz Eidens Ph.D. | Chief Science Officer & Executive Director |
| Philipp Freese | Chief Business Officer |
| Stefan Erlach | Head of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 6-K | Filing |
| Dec 16, 2024 | 6-K | Filing |
| Dec 16, 2024 | 424B3 | Filing |
| Dec 13, 2024 | 6-K | Filing |
| Dec 11, 2024 | F-1/A | [Amend] Filing |
| Dec 09, 2024 | F-1/A | [Amend] Filing |
| Dec 09, 2024 | F-1/A | [Amend] Filing |
| Nov 29, 2024 | 6-K | Filing |
| Nov 15, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |